$ALGN

Align Technology options: bullish $220 call dominates flow as ALGN stock slides

Align Technology (ALGN) stock fell 3.04% to $153.81, but a large bullish options bet was placed: 2,266 Jan 2027 $220 calls, 43% above current price. This represents 82.8% of ALGN's options volume, suggesting a long-term bullish view despite recent declines. Implied volatility fell, but downside protection costs rose, indicating mixed market sentiment.

Original reporting
Published Sep 8, 2026, 2:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 3:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ALGN
Bullish
medium confidence
Mentioned
$ALGN
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ALGNBullishMed
01

Why it matters

Traders can use the dominant $220 call concentration and the IV/skew divergence to gauge whether the market is pricing complacency near term while paying for tail-risk protection.

02

Market read

Options-flow divergence (bullish calls vs falling stock) can affect short-term positioning and volatility expectations even without new fundamentals.

03

What to watch

Without confirmation of the buyer’s identity or whether the position is hedged, the flow could unwind quickly if ALGN continues to underperform, limiting follow-through to the $220 strike.

Relevance 4/10Novelty 4/10Timing: intraday options tape at 10:40 AM ET (Sep 8)

Background

The piece frames ALGN’s intraday decline alongside a large bullish options print and discusses implied volatility and skew behavior.

Company-level read

Ticker impact

$ALGNBullishMedium confidence
Context

Align Technology shares are down 3.04% intraday while a dominant 2,266-contract bullish Jan 15, 2027 $220 call prints 82.8% of options volume.

Expected impact

Near-term price action may remain choppy, but the call concentration can support upside gamma if ALGN stabilizes and rallies toward the $220 strike over time.

Evidence & confidence

The article provides specific options-flow metrics (dominant strike, call/put imbalance, IV and skew changes) but no new fundamental catalyst, so impact is primarily positioning-driven rather than fundamentals-driven.

Market effects

If the bet reflects a broader orthodontics recovery thesis, it could modestly influence sentiment toward medical device names with similar growth narratives, but the article is single-name.

No direct regional transmission is described beyond general market weakness at the open.

No global macro or cross-border corporate linkage is provided beyond generic Fed-rate-hike expectations.

Counterpoint

The bullish call flow may be a hedge or a volatility trade rather than a directional conviction, especially given rising downside skew and falling near-term implied vol.

Key entities

  • Align Technology

    Subject of the article, with ALGN stock down intraday and a dominant bullish Jan 15, 2027 $220 call flow.

Related articles

$ALGNLow

Align Tech adds Quentin Blackford to board

Align Technology (ALGN) added Quentin Blackford, CEO of iRhythm Technologies, to its board, expanding it to 11 members. Blackford brings healthcare and digital innovation experience. Director Andrea L. Saia will retire in September 2026, reducing the board to 10 members.

$ALGNMed

Are Wall Street Analysts Bullish on Align Technology Stock?

Align Technology (ALGN), a medical device company, has underperformed the broader market and healthcare sector ETF over the past 52 weeks. Analysts expect its adjusted EPS to grow 10.9% YoY by 2026, with a consensus 'Moderate Buy' rating. The mean price target is $207.07, implying a 30.1% upside. Piper Sandler maintained a 'Buy' rating with a $235 target.

$ALGNMed

Align Technology Prevails in China Patent Infringement Action Against Angelalign

Align Technology said a Jinan Intermediate People’s Court issued a first-instance ruling on Aug. 10, 2026 in a China patent case against Angel. The court found Angel’s MasterForce and ATreat systems infringe Align’s CN113693748B patent and ordered Angel to stop use, manufacturing, and sales, awarding RMB 10 million in damages. Angel can appeal to China’s Supreme People’s Court.

$ALGNMed

Align Technology, Inc.: Align Technology Prevails in China Patent Infringement Action Against Angelalign

Align Technology (Nasdaq: ALGN) said China’s Jinan Intermediate People’s Court ruled in its favor in a patent infringement case against Angelalign’s China subsidiaries. The court found Angel infringed Align’s CN113693748B patent tied to extraction-gap-closure technology, ordering a stop to use and sales in China and awarding RMB 10 million in damages. Angel can appeal.

$DDDMed

3D Printing Financials: 3D Systems, Prodways, and Align Build on Positive Momentum - 3DPrint.com

3D Systems reported Q2 revenue of $94.6M, flat YoY, with healthcare up 6.8% and aerospace/defense and data center infrastructure each growing over 20%. Adjusted EBITDA loss narrowed to $0.8M. It expects Q3 revenue of $96M to $99M. Prodways posted Q2 revenue of €10.5M (+5% YoY) and plans a €20M buyback. Align Technology reported record Q2 revenue of just over $1.05B (+4.3%), with clear aligner revenue up 8.2% and 2026 revenue growth guidance of 3% to 4%.

$ALGNMedAI 9/10

Align Technology (ALGN) Q2 2026 Earnings Call Transcript

Align Technology (ALGN) reported Q2 2026 revenue of $1,056.2 million, up 4.3% y/y, driven by record Clear Aligner volumes and higher ASPs. Clear Aligner revenue rose 8.2% to $870.9 million on 691,785 cases. Systems and Services revenue fell 10.8% to $185.3 million. Q3 revenue guidance is $1.00 to $1.02 billion; full-year growth 3% to 4%.